[go: up one dir, main page]

WO2004037226B1 - Compositions pharmaceutiques renfermant de la venlafaxine - Google Patents

Compositions pharmaceutiques renfermant de la venlafaxine

Info

Publication number
WO2004037226B1
WO2004037226B1 PCT/IL2003/000862 IL0300862W WO2004037226B1 WO 2004037226 B1 WO2004037226 B1 WO 2004037226B1 IL 0300862 W IL0300862 W IL 0300862W WO 2004037226 B1 WO2004037226 B1 WO 2004037226B1
Authority
WO
WIPO (PCT)
Prior art keywords
core
venlafaxine
outer coating
water
burst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2003/000862
Other languages
English (en)
Other versions
WO2004037226A3 (fr
WO2004037226A2 (fr
Inventor
Adel Penhasi
Mila Gomberg
Avi Avramoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexcel Pharma Technologies Ltd
Original Assignee
Dexcel Pharma Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/280,084 external-priority patent/US6703044B1/en
Application filed by Dexcel Pharma Technologies Ltd filed Critical Dexcel Pharma Technologies Ltd
Priority to EP03758627A priority Critical patent/EP1558222A2/fr
Priority to US10/532,407 priority patent/US20060057204A1/en
Priority to CA002503380A priority patent/CA2503380A1/fr
Priority to AU2003274655A priority patent/AU2003274655A1/en
Publication of WO2004037226A2 publication Critical patent/WO2004037226A2/fr
Publication of WO2004037226A3 publication Critical patent/WO2004037226A3/fr
Publication of WO2004037226B1 publication Critical patent/WO2004037226B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation retard à libération progressive comprenant un noyau présenté sous la forme d'une pastille comprimée et un enrobage externe entourant le noyau renfermant la venlafaxine ou un sel acceptable sur le plan pharmaceutique de celle-ci, au moins un agent de commande de décharge et un désintégrant; l'enrobage externe comprenant un véhicule hydrophobe insoluble dans l'eau et une matière particulaire insoluble dans l'eau mais hydrophile.
PCT/IL2003/000862 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine Ceased WO2004037226A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03758627A EP1558222A2 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine
US10/532,407 US20060057204A1 (en) 2002-10-25 2003-10-23 Pharmaceutical compositions containing venlafaxine
CA002503380A CA2503380A1 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine
AU2003274655A AU2003274655A1 (en) 2002-10-25 2003-10-23 Pharmaceutical compositions containing venlafaxine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/280,084 2002-10-25
US10/280,084 US6703044B1 (en) 2002-10-25 2002-10-25 Venlafaxine formulations
IL158,493 2003-10-20
IL15849303A IL158493A0 (en) 2002-10-25 2003-10-20 Pharmaceutical compositions containing venlafaxine

Publications (3)

Publication Number Publication Date
WO2004037226A2 WO2004037226A2 (fr) 2004-05-06
WO2004037226A3 WO2004037226A3 (fr) 2004-07-08
WO2004037226B1 true WO2004037226B1 (fr) 2004-09-10

Family

ID=32178938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000862 Ceased WO2004037226A2 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine

Country Status (4)

Country Link
EP (1) EP1558222A2 (fr)
AU (1) AU2003274655A1 (fr)
CA (1) CA2503380A1 (fr)
WO (1) WO2004037226A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520547A (ja) * 2004-02-04 2007-07-26 アレムビック・リミテッド ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
US20090175934A1 (en) * 2006-03-08 2009-07-09 Jubilant Organosys Ltd. Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
WO2007112574A1 (fr) * 2006-04-03 2007-10-11 Isa Odidi Composition de venlafaxine à libération prolongée
HUE041795T2 (hu) * 2010-08-31 2019-05-28 Toray Industries Bevonószer szilárd gyógyszerészeti készítményhez, gyógyszerészeti filmkészítmény, és bevonatos szilárd gyógyszerészeti készítmény
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
WO2003055475A1 (fr) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Formulation pharmaceutique a liberation controlee contenant de la venlafaxine

Also Published As

Publication number Publication date
AU2003274655A8 (en) 2004-05-13
WO2004037226A3 (fr) 2004-07-08
CA2503380A1 (fr) 2004-05-06
AU2003274655A1 (en) 2004-05-13
WO2004037226A2 (fr) 2004-05-06
EP1558222A2 (fr) 2005-08-03

Similar Documents

Publication Publication Date Title
CA2446712C (fr) Systeme d'administration osmotique d'agents pharmaceutiquement actifs
CA2294744C (fr) Forme galenique effervescente constituee d'unites multiples
ES2355099T3 (es) Dispositivo osmótico dentro de un dispositivo osmótico.
JP5572616B2 (ja) 口腔内分散性多層錠剤
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
AU2002303897A1 (en) System for osmotic delivery of pharmaceutically active agents
IL211075A (en) Multi-component preparation with irregular release
KR20030013460A (ko) 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형
CA2025703A1 (fr) Systemes pulsatiles pour la dispensation une fois par jour de minocycline
WO2007000778A3 (fr) Compositions pharmaceutiques a liberation modifiee et leurs procedes
KR20160135373A (ko) 주의력 결핍 장애의 치료를 위한 방법 및 조성물
CA2628200A1 (fr) Compositions pharmaceutiques solides contenant de la pregabaline
EP1909770B1 (fr) Composition a liberation orale controlee contenant du levetiracetam
US6080427A (en) Cefadroxil monohydrate tablet formulation
CA2330480A1 (fr) Preparation a liberation controlee de divalproex sodium
CA2486859A1 (fr) Association de formes posologiques de levodopa/carbidopa a liberation immediate et controlee
SG146638A1 (en) Pharmaceutical delivery system
JP2002530322A5 (fr)
JP2005528430A5 (fr)
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
KR20240101826A (ko) 인지 장애를 치료하기 위한 방법 및 조성물
EP1679066A1 (fr) Microparticule enrobee contenant un medicament pour comprime a dissolution orale
WO2004037226B1 (fr) Compositions pharmaceutiques renfermant de la venlafaxine
MXPA04009906A (es) Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda.
RU2002109236A (ru) Композиции с контрлируемым высвобождением для перорального применения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20040726

ENP Entry into the national phase

Ref document number: 2006057204

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2503380

Country of ref document: CA

Ref document number: 10532407

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003758627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003758627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10532407

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP